4D Molecular Therapeutics Net Income
| FDMT Stock | USD 8.86 0.11 1.23% |
As of the 31st of January, 4D Molecular owns the Market Risk Adjusted Performance of (0.21), information ratio of (0.05), and Variance of 27.96. 4D Molecular Therapeutics technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices.
4D Molecular Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 1.3 K | Revenue | Earnings Share (3.75) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -144.8 M | -137.5 M | |
| Net Loss | -96.7 M | -91.9 M | |
| Net Loss | -144.8 M | -137.5 M | |
| Net Loss | (3.43) | (3.60) |
FDMT | Net Income | Build AI portfolio with FDMT Stock |
The evolution of Net Income for 4D Molecular Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how 4D Molecular compares to historical norms and industry peers.
Latest 4D Molecular's Net Income Growth Pattern
Below is the plot of the Net Income of 4D Molecular Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in 4D Molecular Therapeutics financial statement analysis. It represents the amount of money remaining after all of 4D Molecular Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is 4D Molecular's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in 4D Molecular's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (160.87 M) | 10 Years Trend |
|
Net Income |
| Timeline |
FDMT Net Income Regression Statistics
| Arithmetic Mean | (54,043,255) | |
| Coefficient Of Variation | (101.24) | |
| Mean Deviation | 46,093,124 | |
| Median | (11,223,000) | |
| Standard Deviation | 54,714,877 | |
| Sample Variance | 2993.7T | |
| Range | 151.3M | |
| R-Value | (0.89) | |
| Mean Square Error | 642.5T | |
| R-Squared | 0.80 | |
| Slope | (9,683,965) | |
| Total Sum of Squares | 47899.5T |
FDMT Net Income History
Other Fundumenentals of 4D Molecular Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
FDMT Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for 4D Molecular is extremely important. It helps to project a fair market value of FDMT Stock properly, considering its historical fundamentals such as Net Income. Since 4D Molecular's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of 4D Molecular's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of 4D Molecular's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will FDMT introduce new products? Factors like these will boost the valuation of 4D Molecular. Market participants price FDMT higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about 4D Molecular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.75) | Revenue Per Share | Quarterly Revenue Growth 29 | Return On Assets | Return On Equity |
4D Molecular Therapeutics's market price often diverges from its book value, the accounting figure shown on FDMT's balance sheet. Smart investors calculate 4D Molecular's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since 4D Molecular's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between 4D Molecular's value and its price as these two are different measures arrived at by different means. Investors typically determine if 4D Molecular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 4D Molecular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
4D Molecular 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to 4D Molecular's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of 4D Molecular.
| 11/02/2025 |
| 01/31/2026 |
If you would invest 0.00 in 4D Molecular on November 2, 2025 and sell it all today you would earn a total of 0.00 from holding 4D Molecular Therapeutics or generate 0.0% return on investment in 4D Molecular over 90 days. 4D Molecular is related to or competes with Kalvista Pharmaceuticals, Omeros, Bicycle Therapeutics, Gossamer Bio, Lexicon Pharmaceuticals, ADC Therapeutics, and Neumora Therapeutics. 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-asso... More
4D Molecular Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure 4D Molecular's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess 4D Molecular Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 28.25 | |||
| Value At Risk | (9.30) | |||
| Potential Upside | 7.04 |
4D Molecular Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for 4D Molecular's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as 4D Molecular's standard deviation. In reality, there are many statistical measures that can use 4D Molecular historical prices to predict the future 4D Molecular's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (0.60) | |||
| Treynor Ratio | (0.22) |
4D Molecular January 31, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.21) | |||
| Mean Deviation | 3.93 | |||
| Coefficient Of Variation | (2,498) | |||
| Standard Deviation | 5.29 | |||
| Variance | 27.96 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (0.60) | |||
| Treynor Ratio | (0.22) | |||
| Maximum Drawdown | 28.25 | |||
| Value At Risk | (9.30) | |||
| Potential Upside | 7.04 | |||
| Skewness | (0.85) | |||
| Kurtosis | 2.26 |
4D Molecular Therapeutics Backtested Returns
4D Molecular Therapeutics retains Efficiency (Sharpe Ratio) of -0.0449, which signifies that the company had a -0.0449 % return per unit of price deviation over the last 3 months. 4D Molecular exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm 4D Molecular's Market Risk Adjusted Performance of (0.21), variance of 27.96, and Information Ratio of (0.05) to double-check the risk estimate we provide. The firm owns a Beta (Systematic Risk) of 1.03, which signifies a somewhat significant risk relative to the market. 4D Molecular returns are very sensitive to returns on the market. As the market goes up or down, 4D Molecular is expected to follow. At this point, 4D Molecular Therapeutics has a negative expected return of -0.24%. Please make sure to confirm 4D Molecular's potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if 4D Molecular Therapeutics performance from the past will be repeated sooner or later.
Auto-correlation | 0.38 |
Below average predictability
4D Molecular Therapeutics has below average predictability. Overlapping area represents the amount of predictability between 4D Molecular time series from 2nd of November 2025 to 17th of December 2025 and 17th of December 2025 to 31st of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of 4D Molecular Therapeutics price movement. The serial correlation of 0.38 indicates that just about 38.0% of current 4D Molecular price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.38 | |
| Spearman Rank Test | 0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.32 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
FDMT Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, 4D Molecular Therapeutics reported net income of (160.87 Million). This is 147.14% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 128.17% higher than that of the company.
FDMT Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 4D Molecular's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 4D Molecular could also be used in its relative valuation, which is a method of valuing 4D Molecular by comparing valuation metrics of similar companies.4D Molecular is currently under evaluation in net income category among its peers.
4D Molecular Current Valuation Drivers
We derive many important indicators used in calculating different scores of 4D Molecular from analyzing 4D Molecular's financial statements. These drivers represent accounts that assess 4D Molecular's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of 4D Molecular's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 608.4M | 718.5M | 792.8M | 300.5M | 345.5M | 328.3M | |
| Enterprise Value | 471.9M | 682.3M | 558.3M | 175.7M | 202.1M | 192.0M |
4D Molecular ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, 4D Molecular's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to 4D Molecular's managers, analysts, and investors.Environmental | Governance | Social |
4D Molecular Institutional Holders
Institutional Holdings refers to the ownership stake in 4D Molecular that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of 4D Molecular's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing 4D Molecular's value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 918.5 K | Bank Of America Corp | 2025-06-30 | 897.1 K | Jpmorgan Chase & Co | 2025-06-30 | 888 K | Two Sigma Advisers, Llc | 2025-06-30 | 743.4 K | Assenagon Asset Management Sa | 2025-06-30 | 648.8 K | Two Sigma Investments Llc | 2025-06-30 | 531.2 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2025-06-30 | 514.6 K | Northern Trust Corp | 2025-06-30 | 329 K | Peapod Lane Capital Llc | 2025-06-30 | 318.5 K | Bvf Inc | 2025-06-30 | 4.6 M | Ra Capital Management, Llc | 2025-06-30 | 4.6 M |
FDMT Fundamentals
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (655.39) % | ||||
| Current Valuation | 155.87 M | ||||
| Shares Outstanding | 51.01 M | ||||
| Shares Owned By Insiders | 3.61 % | ||||
| Shares Owned By Institutions | 79.90 % | ||||
| Number Of Shares Shorted | 9.48 M | ||||
| Price To Book | 1.19 X | ||||
| Price To Sales | 4,271 X | ||||
| Revenue | 37 K | ||||
| Gross Profit | (177.96 M) | ||||
| EBITDA | (181.14 M) | ||||
| Net Income | (160.87 M) | ||||
| Cash And Equivalents | 241.09 M | ||||
| Cash Per Share | 7.45 X | ||||
| Total Debt | 24.61 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 17.20 X | ||||
| Book Value Per Share | 7.89 X | ||||
| Cash Flow From Operations | (134.59 M) | ||||
| Short Ratio | 8.09 X | ||||
| Earnings Per Share | (3.75) X | ||||
| Price To Earnings To Growth | (0.07) X | ||||
| Target Price | 33.11 | ||||
| Number Of Employees | 227 | ||||
| Beta | 2.98 | ||||
| Market Capitalization | 512.5 M | ||||
| Total Asset | 560.38 M | ||||
| Retained Earnings | (576.2 M) | ||||
| Working Capital | 405.78 M | ||||
| Net Asset | 560.38 M |
About 4D Molecular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 4D Molecular Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 4D Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 4D Molecular Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.